Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Sankt Augustin – page 29

1 118 clinical trials in Sankt Augustin, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Sankt Augustin at a glance
1 118
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 118 trials in Sankt Augustin

Open in trial search

Gastric cancer+3

Recruiting

Study of BOLD-100 with FOLFOX chemotherapy (fluorouracil, folinic acid, and oxaliplatin) in patients with advanced gastrointestinal tumors, colorectal, gastric, or pancreatic cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Bold Therapeutics Inc.

Metastases to central nervous system+1

Recruiting

Study on the Safety and Effectiveness of Repotrectinib for Patients with ROS1-Positive Non-Small Cell Lung Cancer and Active Brain Metastasis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Medica Scientia Innovation Research S.L.

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Centre Leon Berard

Colorectal cancer metastatic

Recruiting

Study on Chemotherapy with Irinotecan, Fluorouracil, and Oxaliplatin for Patients with Metastatic Colorectal Cancer After Surgery or Ablation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Dry age-related macular degeneration

Recruiting

Study on Long-term Safety of JNJ-81201887 for Patients with Geographic Atrophy Due to Age-related Macular Degeneration

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Janssen Cilag International

Breast cancer+1

Recruiting

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Alport's syndrome

Recruiting

Study on Dapagliflozin for Slowing Kidney Disease in Adolescents and Young Adults with Alport Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Dapagliflozin
  • Sponsor:Universitaetsmedizin Goettingen

B-cell lymphoma+2

Recruiting

Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tisagenlecleucel
  • Sponsor:Novartis Pharma Services AG

Hepatocellular carcinoma

Recruiting

Study on Fecal Microbiota Transfer with Vancomycin, Atezolizumab, and Bevacizumab for Patients with Advanced Liver Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Plasma cell myeloma

Recruiting

Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Other cities in Germany

The busiest research cities in the country

All 506 cities in Germany

Clinical research in Sankt Augustin

What the registry says about research in the country

01 Pediatric Rheumatology

Clinical trials focusing on innovative treatments for juvenile arthritis conditions, including studies of medications like baricitinib, ustekinumab, and bimekizumab for various forms of JIA.

  • Juvenile Psoriatic Arthritis
  • Systemic Juvenile Idiopathic Arthritis
  • Enthesitis-related Arthritis

Research aims to evaluate drug efficacy and safety in pediatric populations with autoimmune conditions.

02 Pediatric Oncology

Comprehensive studies on childhood cancers, with particular focus on leukemia and lymphoma treatments, including novel therapeutic approaches and combination therapies.

  • Acute Lymphoblastic Leukemia
  • B-cell Lymphoma
  • Myeloid Leukemia

Investigations include targeted therapies and personalized treatment protocols for various cancer stages.

03 Neuro-Oncology

Specialized research into brain and nervous system tumors, focusing on ependymoma and medulloblastoma treatment strategies.

  • Medulloblastoma
  • Intracranial Ependymoma
  • Neuroblastoma

Studies evaluate surgical outcomes, radiation therapy approaches, and chemotherapy effectiveness.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.